Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers

Drug and Alcohol Dependence

Volumn 126, Issue 1-2, 2012, Pages 183-188

  Vourvahis, Manoli ^a   Wang, Rong ^a   Gruener, Daniel Mark ^b   Bruce, R Douglas ^c   Haider, Seema ^a   Tawadrous, Margaret ^a  

^a PFIZER INC   (United States)

^b CRI Worldwide ^*  (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Interaction; Lersivirine; Methadone; NNRTI; Opioid

Indexed keywords

LERSIVIRINE; METHADONE;

ADULT; ARTICLE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; INSOMNIA; MAINTENANCE THERAPY; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; PUPIL; RATING SCALE; SHORT OPIATE WITHDRAWAL SCALE; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VITAL SIGN; VOLUNTEER; VOMITING; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; NITRILES; PUPIL; PYRAZOLES; QUESTIONNAIRES; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; SUBSTANCE WITHDRAWAL SYNDROME; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84867881180     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.05.009     Document Type: Article

References (18)

1. Corbau R., Mori J., Phillips C., Fishburn L., Martin A., Mowbray C., Panton W., Smith-Burchnell C., Thornberry A., Ringrose H., Knochel T., Irving S., Westby M., Wood A., Perros M. Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2010, 54:4451-4463.
2. Covidien, 2009. Methadone hydrochloride oral concentrate USP prescribing information. Available at: , (accessed November, 2011). http://pharmaceuticals.covidien.com/imageServer.aspx/doc191649.pdf?contentID=15861&contenttype=application/pdf.
3. Crauwels H.M., Kakuda T.N. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 2010, 49:67-68.
4. Davis J., Asken E., Stafford H., Hackman F., Weissgerber G., Jenkins T. Safety, toleration and pharmacokinetics of single and mulitple oral doses of UK-453,061, a novel NNRTI, in healthy male subjects. Poster 109 Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention 22-25 July 2007.
5. Davis J., Langdon G., Layton G., Chong C., Ndongo M.-N., Weissgerber G., Vourvahis M. The effect of UK-453,061, a next-generation NNRTI, on the steady state pharmacokinetics of zidovudine, midazolam and contraceptive steroids. Poster P25 Presented at the 9th IWCPHIV 2008.
6. Davis J., Langdon G., Layton G., Chong C.L., Ndongo M.-N., Vourvahis M. The effect of lersivirine (UK-453,061), a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects. Eur. J. Clin. Pharmacol. 2012, [Epub ahead of print].
7. Dowty M.E., Messing D.M., Lai Y., Kirkovsky L. ADMET for Medicinal Chemists: A Practical Guide 2011, Wiley, Hoboken.
8. Esteban J., Pellin M.L., Gimeno C., Barril J., Gimenez J., Mora E., Garcia-Perez A.G. Increase of R-/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz. Drug Metab. Lett. 2008, 2:269-274.
9. Fätkenheuer G., Staszewski S., Plettenburg A., Hackman F., Layton G., McFadyen L., Davis J., Jenkins T.M. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS 2009, 23:2115-2122.
10. Hassan H.E., Myers A.L., Coop A., Eddington N.D. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J. Pharm. Sci. 2009, 98:4928-4940.
11. Langdon G., Davis J., Layton G., Choo H.W., Ndongo M.-N., Milton A., Vourvahis M. Pharmacokinetic interactions of the next-generation NNRTI UK-453,061 with other antiretrovirals and assessment of safety and tolerability in healthy male subjects. Poster 763 Presented at the 15th Conference on Retroviruses and Opportunistic Infections 2008.
12. Mathers B.M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S.A., Wodak A., Panda S., Tyndall M., Toufik A., Mattick R.P. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008, 372:1733-1745.
13. Mori J., Corbau R., Lewis D., Ellery S., Mayer H., Perros M., Westby M. In vitro characterization of UK-453,061, a non-nucleoside reverse transcriptase inhibitor. Abstract 728 Presented at the 15th Conference on Retroviruses and Opportunistic Infections 2008.
14. Phillips C., Irving S., Ringrose H., Corbau R., Mowbray C. HIV-1 reverse transcriptase structure-based drug design: crystals to clinic. Acta Cryst. 2007, A63. s18.
15. Scholler-Gyure M., van den B.W., Kakuda T.N., Woodfall B., De S.G., Vanaken H., Stevens T., Peeters M., Vandermeulen K., Hoetelmans R.M. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J. Clin. Pharmacol. 2008, 48:322-329.
16. Shiran M.R., Lennard M.S., Iqbal M.Z., Lagundoye O., Seivewright N., Tucker G.T., Rostami-Hodjegan A. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br. J. Clin. Pharmacol. 2009, 67:29-37.
17. Vourvahis M., LaBadie R., Fang J., Banerjee S., Ndongo M.-N. Lack of a clinically relevant effect of UK-453,061, a next generation NNRTI, on the pharmacokinetics of atazanavir±ritonavir and antacid on the pharmacokinetics of UK-453,061 in healthy subjects. Poster Presented at the 10th IWCPHIV 2009, 15-17. April.
18. Vourvahis M., Gleave M., Nedderman A.N., Hyland R., Gardner I., Howard M.R., Kempshall S., Collins C., LaBadie R. Excretion and metabolism of lersivirine (UK-453,061), a next generation NNRTI, following administration of [14C] lersivirine to healthy volunteers. Drug Metab. Dispos. 2010, 38:789-800.